Skip to main content
. 2020 Nov 20;10:20277. doi: 10.1038/s41598-020-77171-2

Table 3.

In vitro CYP Inhibition with VZHE-039.

Enzyme Substrate IC50 (μM)
Control Inhibitor VZHE-039
CYP1A2 Tacrine α-Naphthoflavone (0.005) 4.7
CYP2C8 Amodiaquine Quercetin (1.2–1.75)  > 100
CYP2C9 Tolbutamide Sulfaphenazole (0.129–0.205)  > 100
CYP2C19 S-Mephentoin Ticlopidine (1.4)  > 100
CYP2D6 Dextromethorphan Quinidine (0.035–0.163)  > 100
CYP3A4 Midazolam Ketoconazole (0.018–0.0234)  > 100
CYP3A4 Testosterone Ketoconazole (0.015–0.019) 95.0
CYP2B6 Bupropion Ticlopidine (0.250) 41.4